Table 3.
Neutralization by MAb B4 and MAb IgG2b12 of a panel of HIV-1 primary isolates from subtypes A-F, by MT-2 microplaque assay
| Virus strain | Subtype | mAb B4 concentration at 90% neutralization in replicate experiments, μg/ml
|
mAb IgG1b12 concentration at 90% neutralization, μg/ml
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Preincubate B4 with virus | Preincubate B4 with cell | Preincubate b12 with virus | ||||||||
| UG/92/029 | A | 6.8 | 1.0 | 3.4 | 3.7 | 38.5 | ||||
| DH 12 | B | 2.1 | 1.7 | 4.3 | 3.0 | ND | ||||
| VL 135 | B | 1.5 | 1.2 | 0.27 | 0.77 | 0.85 | 0.54 | 0.84 | 1.1 | ND |
| BR/92/014 | B | 1.6 | 0.75 | ND | >50 | |||||
| ZIM 748 | C | 2.8 | 0.23 | 0.35 | 0.34 | >50 | ||||
| UG 266 | D | 25 | 11 | 38 | 31 | >50 | ||||
| TH 32036 | E | 3.3 | 0.25 | 1.1 | 0.52 | >50 | ||||
| BR/93/020 | F | 15 | 18 | ND | ||||||
| MN | B | 66.7 | ND | 0.91 | ||||||
Antibody was preincubated with either virus or with cells as indicated. The multiple numbers in columns 3 and 4 represent 90% neutralization titers determined in independent assays. The primary isolates originated in various regions of the world: VL135 (North America), UG/92/029 (Uganda), BR/92/014 and BR/93/020 (Brazil), ZIM748 (Zimbabwe), UG266 (Uganda), and TH32036 (Thailand). ND, not determined.